Suppr超能文献

从诊断到耐药:miRNAs 在嗜铬细胞瘤进展和治疗反应中的交响乐。

From diagnosis to resistance: a symphony of miRNAs in pheochromocytoma progression and treatment response.

机构信息

Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11231, Cairo, Egypt.

Department of Biochemistry, Faculty of Pharmacy, Heliopolis University, Cairo, 11785, Egypt.

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr;397(4):1957-1969. doi: 10.1007/s00210-023-02759-0. Epub 2023 Oct 6.

Abstract

Pheochromocytoma (PCC) is a neuroendocrine tumor that produces and secretes catecholamine from either the adrenal medulla or extra-adrenal locations. MicroRNAs (miRNAs, miR) can be used as biomarkers to detect cancer or the return of a previously treated disease. Blood-borne miRNAs might be envisioned as noninvasive markers of malignancy or prognosis, and new studies demonstrate that microRNAs are released in body fluids as well as tissues. MiRNAs have the potential to be therapeutic targets, which would greatly increase the restricted therapy options for adrenal tumors. This article aims to consolidate and synthesize the most recent studies on miRNAs in PCC, discussing their potential clinical utility as diagnostic and prognostic biomarkers while also addressing their limitations.

摘要

嗜铬细胞瘤(PCC)是一种神经内分泌肿瘤,它可以从肾上腺髓质或肾上腺外部位产生和分泌儿茶酚胺。microRNAs(miRNAs,miR)可用作生物标志物来检测癌症或以前治疗疾病的复发。血源性miRNAs 可以被视为恶性或预后的非侵入性标志物,新的研究表明,miRNAs 也会从体液和组织中释放出来。miRNAs 具有作为治疗靶点的潜力,这将极大地增加肾上腺肿瘤的有限治疗选择。本文旨在整合和综合 PCC 中 miRNAs 的最新研究,讨论其作为诊断和预后生物标志物的潜在临床应用,同时也解决其局限性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验